MAPK3 and prostate carcinoma: To analyze the synergistic effect of hesperidin with inhibitors of the PI3K and MAPK signaling pathways, we co-treated prostate cancer cells with LY294002 (PI3K inhibitor), U0126 (ERK1/2 inhibitor), and SB203580 (P38 inhibitor).